Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 6/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 5/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 5/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | CETP | P11597 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21166114 | 0.92 | GNAO1 (0.43) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL21524575 | 0.90 | GNAO1 (0.44) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL19302473 | 0.90 | GNAO1 (0.44) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL4893032 | 0.90 | GNAO1 (0.43) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL18431542 | 0.88 | GNAO1 (0.46) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL19485353 | 0.88 | GNAO1 (0.46) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL18649667 | 0.88 | GNAO1 (0.46) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL18993485 | 0.88 | GNAO1 (0.46) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL19226663 | 0.88 | GNAO1 (0.46) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL25583622 | 0.86 | GNAO1 (0.39) | GNAO1GNAI3GNAI1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647686-B2 | Substituted pyrimidines for preventing or treating cancer and inflammatory diseases | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2020-05-12 | — | — | US | disclosed |
| US-20190284143-A1 | NOVEL PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER AND INFLAMMATORY DISEASES | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284143-A1 | NOVEL PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER AND INFLAMMATORY DISEASES | DTYMK, TGFB1, DCK | GNAO1 2467/4885GNAI3 3248/4885GNAI1 2245/4885 |
| US-10647686-B2 | Substituted pyrimidines for preventing or treating cancer and inflammatory diseases | TGFBR1, TGFBR2, TGFB1 | GNAO1 2270/4885GNAI3 2840/4885GNAI1 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.